An antidepressant commonly used to treat obsessive-compulsive disorder (OCD) may significantly reduce the risk of clinical deterioration in COVID-19 patients, according to new research published in Scientific Reports.
A systematic review and meta-analysis of 14 clinical studies involving 7,153 patients found that early treatment with fluvoxamine, especially at doses of 200 milligrams or more, notably reduced COVID-19 clinical deterioration, mortality, and long-COVID complications.
